Kronos Bio, Inc. (KRON)
0.8800
0.00 (0.00%)
Inactive · Last trade price on Jun 20, 2025
Kronos Bio Revenue
Kronos Bio had revenue of $1.86M in the quarter ending March 31, 2025, a decrease of -26.03%. This brings the company's revenue in the last twelve months to $9.19M, up 21.15% year-over-year. In the year 2024, Kronos Bio had annual revenue of $9.85M with 56.62% growth.
Revenue (ttm)
$9.19M
Revenue Growth
+21.15%
P/S Ratio
5.78
Revenue / Employee
$919,200
Employees
10
Market Cap
53.73M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 9.85M | 3.56M | 56.62% |
| Dec 31, 2023 | 6.29M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionKRON News
- 5 months ago - Kronos Bio Completes Sale to Concentra Biosciences - Market Watch
- 6 months ago - KRONOS BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kronos Bio, Inc. - KRON - Business Wire
- 6 months ago - Kronos Bio Enters into Agreement to Be Acquired by Concentra Biosciences for $0.57 in Cash per Share Plus a Contingent Value Right - GlobeNewsWire
- 8 months ago - Kronos Bio Reports Fourth Quarter and Full Year 2024 Financial Results - GlobeNewsWire
- 1 year ago - Kronos Bio Announces CEO Transition and Reduction in Force - GlobeNewsWire
- 1 year ago - Kronos Bio Highlights Preclinical Data that Show p300 KAT Inhibitors Reduce Inflammation in an Oral Presentation at ACR Convergence 2024 - GlobeNewsWire
- 1 year ago - Kronos Bio Data Presentation at EORTC-NCI-AACR Symposium Highlights the Importance of p300 KAT Inhibition in HPV-Driven Tumors - GlobeNewsWire
- 1 year ago - Kronos Bio to Present Data at the EORTC-NCI-AACR Symposium that Supports p300 KAT Inhibition in HPV-Driven Tumors - GlobeNewsWire